PanAmerican Clinical Research has partnered with Centro de Atención e Investigación Médica (CAIMED) to provide a comprehensive selection of sites in Latin America and to open a research centre in Rio Grande Valley of Texas, the US.
PanAmerican is a US-based firm delivering clinical trial, home visit, and patient recruitment services, while CAIMED is a research site organisation delivering nine sites in Colombia, the Dominican Republic, and Mexico.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The partnership is expected to bolster the core offerings of both organisations in supporting clinical research in Latin America.
The two entities operate 12 clinical trial locations supporting disease indications impacting Hispanic populations and trials for infectious disease, including Covid-19.
The clinical trial location in Brownsville, Texas is a joint research centre promoting Phase I-IV clinical trials in the Rio Grande Valley.
CAIMED’s research infrastructure along with PanAmerican’s community-oriented recruitment and decentralised model will cater to a large patient population.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataPanAmerican president and general counsel Mitchell Parrish said: “PanAmerican is excited to partner with such a renowned research site organisation and global leader in infectious disease and vaccine trials.
“This site alliance offers a one stop shop for research in Latin America. It also brings a brand-new research center to the Rio Grande Valley in Texas, a growing area underrepresented by clinical research.”
CAIMED executive director Dr Humberto Reynales said: “As a leading site organisation supporting clinical research for over a decade, CAIMED is proud to work with PanAmerican to support more trials for the development of critical vaccines and therapies. Our two organisations offer a strong presence in Latin America for quality and compliant research, and now in the Rio Grande Valley as well.”
